Source: Annual Congress 2001 - New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. F. Fitzgerald, B. A. Briggs, A. M. Thompson, D. F. Edwards, R. G. Sturton (Stoke Poges, United Kingdom). A selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models. Eur Respir J 2001; 16: Suppl. 31, 340

Member's Comments

No comment yet.

Related content which might interest you: The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004 Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 Efficacy of the PDE4 inhibitor, BAY 19-8004, in a smoke-induced model of pulmonary inflammation in the guinea pig Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003 The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 PDE isozymes and effects of selective PDE inhibitors on human lung fibroblasts (Fbs) Source: Eur Respir J 2005; 26: Suppl. 49, 551s Year: 2005 Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001 The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006 Phosphodiesterase 4-5 inhibitor (LASSBio596) per os avoided pulmonary mechanical impairment and inflammation produced by microcystin-LR Source: Annual Congress 2009 - Experimental approaches in animals and modelling in humans Year: 2009 The selective PDE4-inhibitor AWD 12-281 inhibits LPS-induced neutrophilia in domestic pig lung, an animal model of COPD: comparison with steroids Source: Eur Respir J 2001; 18: Suppl. 33, 160s Year: 2001 Phosphodiesterase 4 inhibition of β2-integrin adhesion caused by leukotriene B4 and TNF-α in human neutrophils Source: Eur Respir J 2006; 28: 920-928 Year: 2006 NIK-616,a new type of selective PDE IV inhibitor with reduced emetic activity Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002 The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001